AU2092597A

AU2092597A – Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
– Google Patents

AU2092597A – Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
– Google Patents
Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Info

Publication number
AU2092597A

AU2092597A
AU20925/97A
AU2092597A
AU2092597A
AU 2092597 A
AU2092597 A
AU 2092597A
AU 20925/97 A
AU20925/97 A
AU 20925/97A
AU 2092597 A
AU2092597 A
AU 2092597A
AU 2092597 A
AU2092597 A
AU 2092597A
Authority
AU
Australia
Prior art keywords
chemotherapeutic compounds
targeted oligonucleotides
antiproliferative combinations
containing raf
raf
Prior art date
1996-03-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Application number
AU20925/97A
Inventor
Karl-Heinz Altmann
Doriano Fabbro
Thomas Geiger
Brett Monia
Marcel Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1996-03-07
Filing date
1997-02-24
Publication date
1997-09-22

1997-02-24
Application filed by Novartis AG
filed
Critical
Novartis AG

1997-09-22
Publication of AU2092597A
publication
Critical
patent/AU2092597A/en

Status
Abandoned
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 – A61K41/00

A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K33/00—Medicinal preparations containing inorganic active ingredients

A61K33/24—Heavy metals; Compounds thereof

A61K33/243—Platinum; Compounds thereof

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/70—Carbohydrates; Sugars; Derivatives thereof

AU20925/97A
1996-03-07
1997-02-24
Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Abandoned

AU2092597A
(en)

Applications Claiming Priority (3)

Application Number
Priority Date
Filing Date
Title

US61278796A

1996-03-07
1996-03-07

US08612787

1996-03-07

PCT/EP1997/000875

WO1997032604A1
(en)

1996-03-07
1997-02-24
Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Publications (1)

Publication Number
Publication Date

AU2092597A
true

AU2092597A
(en)

1997-09-22

Family
ID=24454663
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU20925/97A
Abandoned

AU2092597A
(en)

1996-03-07
1997-02-24
Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

Country Status (3)

Country
Link

AU
(1)

AU2092597A
(en)

WO
(1)

WO1997032604A1
(en)

ZA
(1)

ZA971936B
(en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

WO1998008528A1
(en)

1996-08-30
1998-03-05
Biomeasure Incorporated
Method of inhibiting fibrosis with a somatostatin agonist

US6953783B1
(en)

1998-10-19
2005-10-11
Methylgene, Inc.
Modulation of gene expression by combination therapy

ES2228119T3
(en)

*

1998-10-19
2005-04-01
Methylgene, Inc.

MODULATION OF THE EXPRESSION OF DNA-METHYL-TRANFERASE THROUGH COMBINATION THERAPY.

EP1243289A3
(en)

*

1998-10-19
2004-03-17
Methylgene, Inc.
Modulation of gene expression by combination therapy

EP1140291B1
(en)

*

1998-12-22
2005-11-23
Warner-Lambert Company Llc
Combination chemotherapy comprising a mitotic inhibitor and a mek inhibitor

AU2001249817A1
(en)

*

2000-04-03
2001-10-15
Hybridon, Inc.
Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes

CA2416015A1
(en)

*

2000-07-18
2002-01-24
Leo Pharma A/S
Matrix metalloproteinase inhibitors

CA2526285A1
(en)

2003-05-15
2004-12-23
Arqule, Inc.
Inhibitors of p38 and methods of using the same

KR20060012622A
(en)

*

2003-05-16
2006-02-08
하이브리돈, 인코포레이티드
Synergistic treatment of cancer using immunomers in conjuction with chemotherapeutic agents

US7829560B2
(en)

2004-07-08
2010-11-09
Arqule, Inc.
1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase

EP2258704A1
(en)

2004-10-19
2010-12-08
ArQule, Inc.
Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase

WO2007139943A2
(en)

*

2006-05-26
2007-12-06
Ico Therapeutics Inc.
Therapeutic drug combinations and delivery systems comprising c-raf kinase antisense polynucleotides for treating ocular diseases and disorders

US9073997B2
(en)

2007-02-02
2015-07-07
Vegenics Pty Limited
Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

WO1994015645A1
(en)

*

1992-12-31
1994-07-21
Texas Biotechnology Corporation
Antisense molecules directed against genes of the raf oncogene family

AU6633694A
(en)

*

1993-04-09
1994-11-08
Board Of Regents Of The University Of Nebraska, The
Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides

1997

1997-02-24
WO
PCT/EP1997/000875
patent/WO1997032604A1/en
active
Application Filing

1997-02-24
AU
AU20925/97A
patent/AU2092597A/en
not_active
Abandoned

1997-03-06
ZA
ZA9701936A
patent/ZA971936B/en
unknown

Also Published As

Publication number
Publication date

ZA971936B
(en)

1997-09-08

WO1997032604A1
(en)

1997-09-12

Similar Documents

Publication
Publication Date
Title

AU2093597A
(en)

1997-09-16

Chemical compounds

ZA9710314B
(en)

1998-05-18

Chemical compounds.

ZA975953B
(en)

1998-01-06

Chemical compounds.

AU2440997A
(en)

1997-10-29

Calixpyrroles, calixpyridinopyrroles and calixpyridines

AU1492397A
(en)

1998-03-26

Desiccant container

ZA975436B
(en)

1997-12-22

Chemical Compounds.

AU2681895A
(en)

1996-02-16

8-aryl-1,6-naphthyridin-5-ones

ZA975951B
(en)

1998-01-06

Chemical compounds.

AU2092597A
(en)

1997-09-22

Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds

AU5259498A
(en)

1998-05-29

Antisense oligonucleotides

AU3340797A
(en)

1998-01-21

Modified oligonucleotides

AUPP433398A0
(en)

1998-07-16

Compounds and processes

ZA975079B
(en)

1998-01-14

Packet radio systems.

AU4720397A
(en)

1998-03-26

Terpenylated diketopiperazines, (drimentines)

AU7104398A
(en)

1998-12-08

Conopeptides auia, auib and auic

AU8682998A
(en)

1999-06-07

Improvement in chemical analyses

AU3166897A
(en)

1998-01-14

Factor vii-binding reagent

EP0678548A3
(en)

1996-09-04

Antimicrobial materials.

AU8228698A
(en)

1999-02-08

Porous container

AU9006998A
(en)

1999-03-29

Desiccant

AU5960896A
(en)

1997-08-11

Oxidation-reduction process

ZA984689B
(en)

1999-12-01

Polymeric materials.

AUPP003297A0
(en)

1997-11-20

4,5-diaryloxazole compounds

AU1018897A
(en)

1997-07-24

Envelope printing

AU3961899A
(en)

1999-11-23

Chemotherapeutic treatment

Download PDF in English

None